Related Experiment Video
Updated: May 29, 2026

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
Published on: October 31, 2025
[New therapeutic approaches for polymyositis and dermatomyositis]
Katalin Dankó1, Melinda Vincze
1Debreceni Egyetem, Orvos- és Egészségtudományi Centrum, Belgyógyászati Intézet III. Belgyógyászati Klinika, Klinikai Immunológia Tanszék, Debrecen. katalin.danko@unideb.hu
Abstract:
Inflammatory myopathies are chronic, immune-mediated diseases characterized with progressive proximal muscle weakness. They encompass a variety of syndromes with protean manifestations. The aims of therapy are to increase muscle strength, prevent the development of contractures, and to manage the systemic manifestations of the disease. This is a complex treatment which requires routine and wide knowledge. The most important task is to recognize the disease and guide the patient to immunologic center. Although the first line of therapy continues to include corticosteroids, there are a multitude of agents available for treating patients with myositis. There are several different immunosuppressive agents which may be applied alone or in combination with each other, as well as an increasing number of novel and exciting biologic agents targeting molecules participating in the pathogenesis of inflammatory myopathy. Physiotherapy and rehabilitation in the remission period may significantly improve the functional outcome of patients with these disorders.
Related Concept Videos
Myocarditis III: Medical Management
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Nephrotic Syndrome II : Assessment and Medical Management